Tasisulam是一种抗肿瘤剂,是通过内源途径导致细胞凋亡的诱导物。
Tasisulam is an antitumor agent and an apoptosis inducer via the intrinsic pathway. Phase 3.
40 μM左右
大约50 mg/kgi.v.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Haritunians T, et al. Oncol Rep. 2008, 20(5), 1237-1242.
分子式 C11H6BrCl2NO3S2 |
分子量 415.11 |
CAS号 519055-62-0 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 80 mg/mL |
Water <1 mg/mL |
Ethanol 80 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01185548 | Lymphoma|Advanced Cancer | Drug: Tolbutamide|Drug: Tasisulam | Eli Lilly and Company | Phase 1 | 2010-07-01 | 2011-04-12 |
NCT01209832 | Advanced Cancer | Drug: Tasisulam|Drug: Midazolam | Eli Lilly and Company | Phase 1 | 2010-09-01 | 2011-04-12 |
NCT01006252 | Melanoma | Drug: Tasisulam|Drug: Paclitaxel | Eli Lilly and Company | Phase 3 | 2009-12-01 | 2011-08-09 |
NCT01258348 | Metastatic Renal Cell Cancer | Drug: Drug: LY573636-sodium|Drug: Sunitinib | Eli Lilly and Company | Phase 1 | 2008-07-01 | 2012-04-13 |
NCT01214668 | Solid Tumors | Drug: LY573636|Drug: Liposomal Doxorubicin | Eli Lilly and Company | Phase 1 | 2009-01-01 | 2012-02-10 |
NCT00992225 | Breast Cancer | Drug: LY573636 | Eli Lilly and Company | Phase 2 | 2009-09-01 | 2011-08-09 |
NCT00490451 | Sarcoma, Soft Tissue | Drug: LY573636 | Eli Lilly and Company | Phase 2 | 2007-08-01 | 2010-12-09 |
NCT00428610 | Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | Drug: LY573636 | Eli Lilly and Company | Phase 2 | 2007-02-01 | 2012-01-31 |
NCT00383292 | Metastatic Melanoma | Drug: LY573636 | Eli Lilly and Company | Phase 2 | 2006-11-01 | 2015-08-21 |
NCT00363766 | Non-Small-Cell Lung Cancer | Drug: LY573636 | Eli Lilly and Company | Phase 2 | 2006-09-01 | 2009-10-16 |
NCT01215916 | Solid Tumors | Drug: LY573636|Drug: Pemetrexed | Eli Lilly and Company | Phase 1 | 2008-02-01 | 2012-02-10 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们